Mylan Institutional Drug Patent Portfolio

Mylan Institutional owns 1 orange book drug protected by 2 US patents Given below is the list of Mylan Institutional's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5866591 Stable formulations of remifentanil 10 Mar, 2018 Expired
US5866591 Stable formulations of remifentanil 10 Sep, 2017 Expired


Mylan Institutional's Family Patents


Family Patents



Recently granted tentative Approvals to Mylan Institutional

These tentative approvals reflect continued regulatory progress across both innovative and generic submissions related to Mylan Institutional's portfolio.

Innovator tentative approvals

Drug Name Active Ingredient Submission Type Submission Category Submission Date
Abacavir And Lamivudine Abacavir;lamivudine ORIG-1
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
Type 3 - New Dosage Form 23 Oct, 2014
Lamivudine; Zidovudine; Efavirenz Lamivudine;zidovudine;efavirenz ORIG-1
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
Type 4 - New Combination 04 Sep, 2014
Lamivudine; Zidovudine Lamivudine; Zidovudine ORIG-1
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
Type 5 - New Formulation or New Manufacturer 04 Feb, 2014

Generic tentative approvals

Drug Name Active Ingredient Submission Type Submission Category Submission Date
Sumatriptan Succinate Sumatriptan Succinate ORIG-1
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
(Not Available) 24 Jan, 2007
Fexofenadine Hcl; Pseudoephedrine Hcl Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride ORIG-1
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
(Not Available) 30 Apr, 2004
Quinapril Hydrochloride Quinapril Hydrochloride ORIG-1
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
(Not Available) 24 May, 2002

Explore deeper patents analysis

Mylan Institutional Drug List

Given below is the complete list of Mylan Institutional's drugs and the patents protecting them.


1. Ultiva

Ultiva is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5866591
(Pediatric)
Stable formulations of remifentanil 10 Mar, 2018
(7 years ago)
Expired
US5866591 Stable formulations of remifentanil 10 Sep, 2017
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ultiva's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List